Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...
She emphasized the positive results of the HELIOS-B Phase 3 study, regulatory filings for vutrisiran in ATTR cardiomyopathy, and the company's transition to profitability with $95 million in non ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results